ELTX (Elicio Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ELTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Carol Gail Ashe | Director | A | — | — |
| 2026-09-02 | Yekaterina Chudnovsky | Director | A | — | — |
| 2026-09-02 | Jay Venkatesan | Director | A | — | — |
| 2026-09-02 | ROBERT R RUFFOLO | Director | A | — | — |
| 2026-09-02 | JULIAN ADAMS | Director | A | — | — |
| 2026-09-02 | Allen Nissenson | Director | A | — | — |
| 2026-09-02 | KAREN J WILSON | Director | A | — | — |
| 2026-07-17 | Peter DeMuth | Chief Scientific Officer | A | — | — |
| 2026-07-17 | Robert Connelly | CEO, President and Director | A | — | — |
| 2026-07-17 | Christopher Haqq | See Remarks | A | — | — |
| 2026-07-17 | Preetam Shah | See Remarks | A | — | — |
| 2026-02-03 | Preetam Shah | See Remarks | A | — | — |
| 2026-02-03 | Robert Connelly | CEO, President and Director | A | — | — |
| 2026-02-03 | Christopher Haqq | See Remarks | A | — | — |
| 2026-02-03 | Peter DeMuth | Chief Scientific Officer | A | — | — |
| 2025-12-10 | Peter DeMuth | Chief Scientific Officer | M | — | — |
| 2025-06-04 | GKCC, LLC | 10%+ Owner | A | — | — |
| 2025-05-20 | Allen Nissenson | Director | A | — | — |
| 2025-05-20 | Carol Gail Ashe | Director | A | — | — |
| 2025-05-20 | KAREN J WILSON | Director | A | — | — |
| 2025-05-20 | ROBERT R RUFFOLO | Director | A | — | — |
| 2025-05-20 | JULIAN ADAMS | Director | A | — | — |
| 2025-05-20 | Jay Venkatesan | Director | A | — | — |
| 2025-05-20 | Yekaterina Chudnovsky | Director | A | — | — |
| 2025-04-16 | Preetam Shah | See Remarks | A | — | — |
| 2025-03-07 | GKCC, LLC | 10%+ Owner | C | — | — |
| 2025-02-04 | Robert Connelly | CEO, President and Director | A | — | — |
| 2025-02-04 | Christopher Haqq | See Remarks | A | — | — |
| 2025-02-04 | Peter DeMuth | Chief Scientific Officer | A | — | — |
| 2025-01-02 | Jay Venkatesan | Director | Buy | — | — |
| 2024-12-18 | Peter DeMuth | Chief Scientific Officer | M | — | — |
| 2024-11-29 | Jay Venkatesan | Director | X | — | — |
| 2024-11-25 | Yekaterina Chudnovsky | Director | A | — | — |
| 2024-11-25 | Jay Venkatesan | Director | A | — | — |
| 2024-11-25 | ROBERT R RUFFOLO | Director | A | — | — |
| 2024-11-25 | Carol Gail Ashe | Director | A | — | — |
| 2024-11-25 | Allen Nissenson | Director | A | — | — |
| 2024-11-25 | JULIAN ADAMS | Director | A | — | — |
| 2024-11-25 | KAREN J WILSON | Director | A | — | — |
| 2024-10-02 | Robert Connelly | CEO, President and Director | A | — | — |
| 2024-10-02 | Christopher Haqq | See Remarks | A | — | — |
| 2024-10-02 | Peter DeMuth | Chief Scientific Officer | A | — | — |
| 2024-08-14 | Yekaterina Chudnovsky | Director | Buy | — | — |
| 2024-07-02 | Jay Venkatesan | Director | Buy | — | — |
| 2024-07-02 | GKCC, LLC | 10%+ Owner | Buy | — | — |
| 2024-03-20 | GKCC, LLC | 10%+ Owner | Buy | — | — |
| 2024-02-05 | Christopher Haqq | See Remarks | A | — | — |
| 2024-02-05 | Robert Connelly | CEO, President and Director | A | — | — |
| 2024-02-05 | Peter DeMuth | Chief Scientific Officer | A | — | — |
| 2024-02-05 | Brian Piekos | Chief Financial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,416,212 | — |
| — | Director | 180,534 | — |
| — | CEO, President and Director | 120,570 | — |
| — | See Remarks | 57,381 | — |
| — | See Remarks | 24,000 | — |
| — | Chief Scientific Officer | 21,543 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ELTX quote page; the site-wide leaderboard is on the insider transactions hub.